(Q33934617)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21679466%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21679466%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21679466%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Jian Ma

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21679466%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Shuiliang Wang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21679466%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Ming Zhao

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21679466%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Xin-Sheng Deng

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21679466%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Choon-Kee Lee

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21679466%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Xiao-Dan Yu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21679466%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

English

0 references

publication date

16 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21679466%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21679466%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21679466%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

255

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21679466%20AND%20SRC:MED&resulttype=core&format=json

Mechanism of action of pentostatin and cladribine in hairy cell leukemia

5 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

Cladribine in the treatment of hairy cell leukemia: initial and subsequent results

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

The role of the insulin-like growth factor 1 receptor axis in multiple myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

Bone marrow microenvironment and the identification of new targets for myeloma therapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

STAT3 as a target for inducing apoptosis in solid and hematological tumors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

Focus on multiple myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

The STATs of cancer--new molecular targets come of age

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141773

Comparison of the effects of 2-chlorodeoxyadenosine and melphalan myeloma cell lines

28 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-255

2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-255

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-255

An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-255

Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-255

Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-255

Beyond hairy cell: the activity of cladribine in other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-255

In vitro assessment of nucleoside analogs in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-255

Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-255

Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-255

HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-255

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-255

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-255

2-Chlorodeoxyadenosine in the treatment of multiple myeloma

21 January 2018

1 reference

12 December 2020

Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine

1 reference

12 December 2020

Biology and treatment of multiple myeloma

1 reference

12 December 2020

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients

1 reference

12 December 2020

Fifth biannual report of the Cochrane Haematologic Malignancies Group--Focus on multiple myeloma

1 reference

12 December 2020

Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells

1 reference

12 December 2020

2-Chlorodeoxyadenosine for multiple myeloma

1 reference

12 December 2020

Epigenetics and microRNAs combine to modulate the MDM2/p53 axis in myeloma

1 reference

12 December 2020

Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion

1 reference

12 December 2020

On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans

1 reference

12 December 2020

Targeting STAT3 in cancer: how successful are we?

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-11-255

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21679466%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

5 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21679466%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

PubMed publication ID

21679466

1 reference